•   
  •   
  •   
W

Canada COVID-19. The Pfizer CEO opposes the lifting of patents on

22:20  06 may  2021
22:20  06 may  2021 Source:   ouest-france.fr

Johnson & Johnson vaccine is coming to Canada. How do we use it best?

  Johnson & Johnson vaccine is coming to Canada. How do we use it best? With an initial shipment of Johnson & Johnson's COVID-19 vaccine due this week — and no word on the next — experts emphasize the need to roll out the shot equitably.Much of the country is in the grips of an alarming third wave. While more vaccines are coming, Johnson & Johnson's (J&J) will offer unique benefits in a time of crisis, said Dr. Isaac Bogoch, an infectious disease specialist based out of Toronto General Hospital.

Albert Bourla, PDG de Pfizer. vaccines © John Thys / AFP Albert Bourla, CEO of Pfizer.

Albert Bourla, the CEO of the American Pharmaceutical Giant Pfizer, said this Thursday, May 6th that it was "not at all" in favor of the US decision to support the temporary suspension of anti-Covid vaccine patents .

The CEO of the American Pharmaceutical Giant Pfizer, Albert Bourla, said Thursday that it was not at all in favor of decision support the temporary suspension of anti-Covid vaccine patents, Emitting in an interview to AFP that it was necessary to increase the production of existing sites.

Read also: Vaccines against COVID-19. What would the patent lifting change?

COVID-19: 1 death, 71 cases in London-Middlesex as region records 10,000th case

  COVID-19: 1 death, 71 cases in London-Middlesex as region records 10,000th case Roughly 2,880 cases have been reported in London-Middlesex just since the month of April began, more than any other month of the pandemic. As of Tuesday, the region's rolling seven-day case average stands at 97, down from 115 the seven days previous. As of the week of April 11, 7.1 per cent of tests in London and Middlesex were coming back positive, down from 7.7 a week earlier, according to data released by MLHU last week.

While Washington supports the temporary suspension of the intellectual property protections for vaccines, in order to accelerate production and distribution, Albert Bourla pointed to open factories manufacturing Biontech-Pfizer Serum elsewhere than in the sites. existing in the United States and the EU (Belgium and Germany).

"Empty promises"

We need to focus our efforts (on existing plants), which have sufficient capacity to produce billions of doses, and make sure we do not disrupt these operations with politically motivated ads. These are empty promises, he said.

A vaccine based on the unpublished technology of the messenger RNA, like the one developed by Pfizer and its German partner Biontech, assumes a very long process and a sharp technical expertise to set up a manufacturing site, explains Albert Bourla.

COVID-19 live updates: With situation improving, Quebec loosens restrictions in some regions

  COVID-19 live updates: With situation improving, Quebec loosens restrictions in some regions Updated throughout the day on Tuesday, May 4. Questions/comments: ariga@postmedia.com Top updates With situation improving, Quebec loosens restrictions in some regions Moderna vaccine shipment will arrive a week early, Trudeau says Canadian pharmacists ‘disappointed,’ worried NACI advice will stoke vaccine hesitancy Quebec reports 797 new cases, 16 deaths as hospitalizations rise 10,000 vaccination appointments remain for people age 55-59, Dubé says Video: ‘Relieved’ Montrealers enjoy extra 90 minutes outside as curfew moves back to 9:30 p.m.

Like Vaccines at RNA messenger had never been produced, the problem is that there are no such factories in the world outside the ones we have built ourselves [...] from nothing, he emphasizes.

Machines specially designed to manufacture the Biontech-Pfizer vaccine formula have been controlled to companies specializing in industrial equipment, and suitable sites to accommodate them.

None of this exists in countries like India and South Africa, he ensures, while these countries, which have many pharmaceutical plants, militate for the lifting of patents.

"bottleneck"

and it is necessary to insist on the bottleneck for raw materials (vaccine components): currently, the smallest gram of raw material produced in the world comes directly to our factories, and does not remain One day in warehouse before being transformed into a vaccine - and each dose, once the quality is controlled, is not stored one day before being delivered, pleads the pattern of Pfizer.

This means that if other places are starting to also control raw material, it may remain stored in their warehouses while waiting for them to find a way to convert it into vaccine doses. It would be a serious setback if it happens, Alarm Albert Bourla.

Pfizer privileges technology transfers and licensing

Biontech-Pfizer ensures the ability to produce up to 3 billion doses this year and more than 3 billion next year.

The German-American duo favors technology transfers and the issuance of targeted licenses to increase the production of its vaccine, reaffirmed Biontech this Thursday, stressing being closely collaborative with more than 15 partners, including Merck laboratories, Novartis, Sanofi and Baxter.

NHL's COVID protocol-related absences for May 8, 2021 .
Players in the protocol are: Colorado's Devan Dubnyk and Washington's Evgeny Kuznetsov.Calgary – TBA

usr: 6
This is interesting!